ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1075

The Impact of Race on Birth Outcomes Among Women with Autoimmune Rheumatic Diseases

Lena Sabih1, Jennifer Strouse 1, Nichole Nidey 2, Gretchen Bandoli 3, Rebecca Baer 4, Sky Feuer 5, Laura Jelliffe-Pawlowski 5, Christina Chambers 6, Kelli Ryckman 2 and Namrata Singh 7, 1University of Iowa Hospitals and Clinics, Iowa City, 2UIOWA, Iowa City, 3University of California, San Diego, La Jolla, 4UCSD, La Jolla, 5UCSF, San Francisco, 6UCSD, San Diego, 7University of Iowa, Iowa City

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: pregnancy, rheumatoid arthritis (RA) and race/ethnicity, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Autoimmune rheumatic diseases (ARDs) are associated with adverse pregnancy outcomes (APOs). There are only a small number of studies that have looked at the association of race with APOs, especially in women of Asian race/ethnicity. Black race has been associated with worse APOs in women with ARDs when compared to Non-Hispanic White populations in a small number of studies. The aim of our study is to evaluate the impact of race and rheumatic disease on birth outcomes including preterm birth (PTB), congenital anomalies, low birth weight (LBW), and small for gestational age (SGA) in a large multiethnic cohort of women.

Methods: Birth records linked to hospital discharge data of singleton births in California from 2007 to 2012 were leveraged for a retrospective cohort study including women at least 18 years old diagnosed with ARD. International classification of diseases, ninth revision codes were used to identify women with ARD, as well as PTB, LBW, SGA and congenital anomalies among infants. Race/ethnicity was abstracted from birth record data. The odds of PTB, LBW, SGA and congenital anomalies were estimated in separate logistic regression models and models were adjusted for maternal age, education, insurance and parity.

Results: Among women with an ARD diagnosis (rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid syndrome, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis) who met our eligibility criteria, Black women had a two-fold increased odds of PTB when compared to Non-Hispanic White women (OR 2.09, 95% CI 1.72-2.53). Additionally, Asian (OR 1.63, 95% CI 1.35-1.96) and Hispanic (OR 1.33, 95% CI 1.16-1.52) women were also more likely to give birth preterm. In women with RA, increased OR of PTB was only significant in Black women compared to Non-Hispanic White women. The odds of SGA were significantly increased for Asian (OR 2.33, 95% CI 1.92-2.83), Black (OR 2.24, 95% CI 1.89-2.89) and Hispanic women with any ARD compared with Non-Hispanic White women and remained significant for those with RA and SLE. Among women with any diagnosis of an ARD, race was not significantly associated with premature rupture of membranes except for Black women (OR 1.53, 95% CI 1.04-2.24).

Conclusion: Our findings support previous work that among women with an ARD diagnosis, minority race is a risk factor for adverse pregnancy outcomes including PTB and SGA. Although the etiology of this increased risk is not fully understood socioeconomic and genetic contributions have been proposed in prior work. Our study is the first study with a large group of women with Asian race/ethnicity and found that this group, along with Hispanic and Black women, have an increased risk of adverse pregnancy outcomes when compared with Non-Hispanic White women. Asian, Black, and Hispanic women with ARDs should undergo increased monitoring during pregnancies.


ARD PTB Table 1 060419

Effect of race on pregnancy outcomes in singleton births of women 18 years and older with ARD in California from 2007 to 2012


Disclosure: L. Sabih, None; J. Strouse, None; N. Nidey, None; G. Bandoli, None; R. Baer, None; S. Feuer, None; L. Jelliffe-Pawlowski, None; C. Chambers, AbbVie, 9, Amgen Inc., 9, Apotex, 9, Barr Laboratories, Inc., Bristol-Myers Squibb, 9, Celgene, GlaxoSmithKline, Janssen Pharmaceuticals, 9, Kali Laboratories, Inc., 9, Pfizer, Inc., 9, Hoffman La Roche-Genentech, Sandoz Pharmaceuticals, 9, Genzyme Sanofi-Aventis, Takeda Pharmaceutical Company Limited, 9, Teva Pharmaceutical Industries Ltd., 9, UCB, USA, 9, Gerber Foundation, 9; K. Ryckman, None; N. Singh, None.

To cite this abstract in AMA style:

Sabih L, Strouse J, Nidey N, Bandoli G, Baer R, Feuer S, Jelliffe-Pawlowski L, Chambers C, Ryckman K, Singh N. The Impact of Race on Birth Outcomes Among Women with Autoimmune Rheumatic Diseases [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/the-impact-of-race-on-birth-outcomes-among-women-with-autoimmune-rheumatic-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-race-on-birth-outcomes-among-women-with-autoimmune-rheumatic-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology